News Archive

Explore how the integration of digital tools and consumer-oriented approaches in clinical trials can enhance participant diversity and recruitment efficiency while addressing challenges in equity, ethics, and security.

Cardiovascular disease is the number one killer of people in the United States and worldwide. Yet physicians often do not prescribe evidence-based medicines that could change those statistics.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no clinical benefit to taking fluticasone furoate for treatment of mild-to-moderate COVID-19 symptoms.

CardioHealth Alliance is announcing a new project sponsored by Amgen aimed at assessing and gathering data regarding how to improve quality of care among patients hospitalized for ASCVD. This work, referred to as the “Test to Treat” project, will be led by cardiovascular disease prevention specialist and DCRI faculty member Neha Pagidipati, MD, MPH.

Researchers have developed a blood test that detects Parkinson’s disease, potentially establishing a way to help diagnose the condition before nervous system damage worsens. A new blood-based diagnostic test would be a major advancement for Parkinson’s disease, which afflicts 10 million people worldwide and is the second-most common neurodegenerative disease after Alzheimer’s. Led by a team of Duke Health neuroscientists, the study appears Aug. 30 in the journal Science Translational Medicine.

Despite numerical improvements in mortality, hospitalizations and exercise ability, data did not reach the pre-specified level of statistical significance.

Newly published research led by the Pediatrix Medical Group and the Duke Clinical Research Institute’s Rachel Greenberg, MD, MB, MHS assessed the impact of COVID-19 on pregnant women and infants admitted to the neonatal intensive care unit (NICU). It is believed to be the largest study evaluating the prevalence of COVID-19 within a diverse neonatal population and associated hospital outcomes.

The design of the clinical trials will allow comparison of multiple interventions across symptom areas for people living with long COVID.

A new partnership with leading global healthcare company Novo Nordisk and the Duke Clinical Research Institute

Three faculty cardiologists from the Duke Clinical Research Institute presented late-breaking research results and shared their insights via panel discussions and moderated posters as part of the E